Oral oncolytics: assessing value of newer agents versus current standards of care as part of PT processes

Oral oncolytics are relatively new to the field of cancer therapy. They currently make up about 25% of the oncology market and their use is continually expanding. The current insurance system is not efficiently equipped to handle the rapid expansion of oral oncolytics into the market, and the curren...

Ausführliche Beschreibung